120 related articles for article (PubMed ID: 8559153)
1. Pep34, a synthetic peptide whose sequence corresponds to the intracytoplasmic domain of the Epstein-Barr virus receptor (CR2, CD21), regulates human B lymphocyte proliferation triggered through CR2.
Balbo M; Barel M; Bouillie S; Drane P; Cassinat B; Frade R
Mol Immunol; 1995 Nov; 32(16):1295-8. PubMed ID: 8559153
[TBL] [Abstract][Full Text] [Related]
2. EBV/C3d receptor (CR2) interacts by its intracytoplasmic carboxy-terminal domain and two distinct binding sites with the p53 anti-oncoprotein and the p68 calcium-binding protein.
Frade R; Gauffre A; Hermann J; Barel M
J Immunol; 1992 Nov; 149(10):3232-8. PubMed ID: 1431101
[TBL] [Abstract][Full Text] [Related]
3. Binding sites of the Epstein-Barr virus and C3d receptor (CR2, CD21) for its three intracellular ligands, the p53 anti-oncoprotein, the p68 calcium binding protein and the nuclear p120 ribonucleoprotein.
Barel M; Balbo M; Gauffre A; Frade R
Mol Immunol; 1995 Apr; 32(6):389-97. PubMed ID: 7753047
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus/C3d receptor (CR2, CD21) activated by its extracellular ligands regulates pp105 phosphorylation through two distinct pathways.
Bouillie S; Barel M; Drane P; Cassinat B; Balbo M; Holers VM; Frade R
Eur J Immunol; 1995 Sep; 25(9):2661-7. PubMed ID: 7589142
[TBL] [Abstract][Full Text] [Related]
5. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.
Carel JC; Myones BL; Frazier B; Holers VM
J Biol Chem; 1990 Jul; 265(21):12293-9. PubMed ID: 1695627
[TBL] [Abstract][Full Text] [Related]
6. A 16 amino acid synthetic peptide derived from human C3d triggers proliferation and specific tyrosine phosphorylation of transformed CR2-positive human lymphocytes and of normal resting B lymphocytes.
Frade R; Hermann J; Barel M
Biochem Biophys Res Commun; 1992 Oct; 188(2):833-42. PubMed ID: 1445326
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats.
Moore MD; Cannon MJ; Sewall A; Finlayson M; Okimoto M; Nemerow GR
J Virol; 1991 Jul; 65(7):3559-65. PubMed ID: 1645784
[TBL] [Abstract][Full Text] [Related]
8. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg.
Guthridge JM; Rakstang JK; Young KA; Hinshelwood J; Aslam M; Robertson A; Gipson MG; Sarrias MR; Moore WT; Meagher M; Karp D; Lambris JD; Perkins SJ; Holers VM
Biochemistry; 2001 May; 40(20):5931-41. PubMed ID: 11352728
[TBL] [Abstract][Full Text] [Related]
9. Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins.
Weis JJ; Toothaker LE; Smith JA; Weis JH; Fearon DT
J Exp Med; 1988 Mar; 167(3):1047-66. PubMed ID: 2832506
[TBL] [Abstract][Full Text] [Related]
10. Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d.
Hutt-Fletcher LM; Fowler E; Lambris JD; Feighny RJ; Simmons JG; Ross GD
J Immunol; 1983 Mar; 130(3):1309-12. PubMed ID: 6218205
[TBL] [Abstract][Full Text] [Related]
11. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.
Nemerow GR; Mold C; Schwend VK; Tollefson V; Cooper NR
J Virol; 1987 May; 61(5):1416-20. PubMed ID: 3033269
[TBL] [Abstract][Full Text] [Related]
12. gp 140, the C3d/EBV receptor (CR2), is phosphorylated upon in vitro activation of human peripheral B lymphocytes.
Barel M; Vazquez A; Charriaut C; Aufredou MT; Galanaud P; Frade R
FEBS Lett; 1986 Mar; 197(1-2):353-6. PubMed ID: 2936622
[TBL] [Abstract][Full Text] [Related]
13. Identification of a partial cDNA clone for the C3d/Epstein-Barr virus receptor of human B lymphocytes: homology with the receptor for fragments C3b and C4b of the third and fourth components of complement.
Weis JJ; Fearon DT; Klickstein LB; Wong WW; Richards SA; de Bruyn Kops A; Smith JA; Weis JH
Proc Natl Acad Sci U S A; 1986 Aug; 83(15):5639-43. PubMed ID: 3016712
[TBL] [Abstract][Full Text] [Related]
14. Activation of the EBV/C3d receptor (CR2, CD21) on human B lymphocyte surface triggers tyrosine phosphorylation of the 95-kDa nucleolin and its interaction with phosphatidylinositol 3 kinase.
Barel M; Le Romancer M; Frade R
J Immunol; 2001 Mar; 166(5):3167-73. PubMed ID: 11207269
[TBL] [Abstract][Full Text] [Related]
15. Infection of human B lymphoma cells by Mycoplasma fermentans induces interaction of its elongation factor with the intracytoplasmic domain of Epstein-Barr virus receptor (gp140, EBV/C3dR, CR2, CD21).
Balbo M; Barel M; Lottin-Divoux S; Jean D; Frade R
FEMS Microbiol Lett; 2005 Aug; 249(2):359-66. PubMed ID: 16054780
[TBL] [Abstract][Full Text] [Related]
16. Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis.
Kovacs JM; Hannan JP; Eisenmesser EZ; Holers VM
J Biol Chem; 2009 Apr; 284(14):9513-20. PubMed ID: 19164292
[TBL] [Abstract][Full Text] [Related]
17. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21).
Esparza I; Becherer JD; Alsenz J; De la Hera A; Lao Z; Tsoukas CD; Lambris JD
Eur J Immunol; 1991 Nov; 21(11):2829-38. PubMed ID: 1834472
[TBL] [Abstract][Full Text] [Related]
18. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.
Guthridge JM; Young K; Gipson MG; Sarrias MR; Szakonyi G; Chen XS; Malaspina A; Donoghue E; James JA; Lambris JD; Moir SA; Perkins SJ; Holers VM
J Immunol; 2001 Nov; 167(10):5758-66. PubMed ID: 11698449
[TBL] [Abstract][Full Text] [Related]
19. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2).
Nemerow GR; Houghten RA; Moore MD; Cooper NR
Cell; 1989 Feb; 56(3):369-77. PubMed ID: 2464439
[TBL] [Abstract][Full Text] [Related]
20. Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection.
Nemerow GR; Mullen JJ; Dickson PW; Cooper NR
J Virol; 1990 Mar; 64(3):1348-52. PubMed ID: 2154612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
